Theralase Technologies Inc.
TLTFF
$0.17
$0.014.06%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 50.24% | -44.75% | -20.11% | 115.47% | -51.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 50.24% | -44.75% | -20.11% | 115.47% | -51.23% |
| Cost of Revenue | -9.58% | -93.44% | -17.96% | 37.15% | -35.43% |
| Gross Profit | 397.85% | -17.45% | -21.67% | 320.59% | -79.83% |
| SG&A Expenses | -12.21% | 7.37% | 3.63% | 6.58% | 1.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.98% | -30.97% | -0.69% | -4.75% | 2.36% |
| Operating Income | 28.51% | 24.88% | -6.39% | 15.39% | -9.75% |
| Income Before Tax | 27.63% | 25.02% | -6.88% | 16.95% | -9.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.63% | 25.02% | -6.88% | 16.95% | -9.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.63% | 25.02% | -6.88% | 16.95% | -9.11% |
| EBIT | 28.51% | 24.88% | -6.39% | 15.39% | -9.75% |
| EBITDA | 29.01% | 26.64% | -6.96% | 15.45% | -10.54% |
| EPS Basic | 31.71% | 26.92% | 0.00% | 22.22% | 0.00% |
| Normalized Basic EPS | 34.62% | 25.00% | 0.00% | 22.73% | 0.00% |
| EPS Diluted | 31.71% | 26.92% | 0.00% | 22.22% | 0.00% |
| Normalized Diluted EPS | 34.62% | 25.00% | 0.00% | 22.73% | 0.00% |
| Average Basic Shares Outstanding | 7.03% | 1.66% | 6.82% | 7.18% | 8.00% |
| Average Diluted Shares Outstanding | 7.03% | 1.66% | 6.82% | 7.18% | 8.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |